Hematology-Oncology – Page 6

Leveraging Functional Immune Profiling to Predict Response in Myeloma Immunotherapy

By MedXY 09/18/2026

This study develops a high-content ex vivo assay of T cell dynamics to predict multiple myeloma patient response to bispecific T cell engager therapies, offering a novel functional biomarker for therapy stratification.

$Innovative CD38-Targeted Bispecific Antibody XmAb18968 Shows Promise in Relapsed/Refractory AML and T-ALL$

Hematology-Oncology news

Innovative CD38-Targeted Bispecific Antibody XmAb18968 Shows Promise in Relapsed/Refractory AML and T-ALL

By MedXY 09/18/2026

A phase 1 trial of XmAb18968, a CD38-CD3 bispecific antibody, demonstrates safety and encouraging efficacy in heavily pretreated relapsed/refractory AML and T-ALL patients, highlighting a novel therapeutic avenue.

$Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study$

Hematology-Oncology news Oncology

Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study

By MedXY 09/18/2026

Lisocabtagene maraleucel demonstrates durable five-year survival and potential cure in relapsed/refractory large B-cell lymphoma, with manageable long-term safety, based on data from the TRANSCEND NHL 001 trial and its long-term follow-up.

Hematology-Oncology news Oncology

NF-κB Driven Transcriptional Signatures in CAR-T Cells Predict Durable Responses in Multiple Myeloma

By MedXY 09/17/2026

Single-cell transcriptomic profiling of ide-cel CAR-T products reveals that intrinsic NF-κB signaling in CD4 CAR-T cells correlates with durable remission in relapsed/refractory multiple myeloma, marking T-cell fitness and potential therapeutic targets for enhancing CAR-T efficacy.

Hematology-Oncology news OB/GYN & Women's Health

Understanding HPA-1a Alloimmunisation in Pregnancy: Insights from a Multi-Ethnic Prospective Study

By MedXY 09/17/2026

This study reveals the population prevalence and incident risk of HPA-1a alloimmunisation in pregnancy across diverse ethnic groups, highlighting its rarity and establishing a framework for risk assessment in foetal-neonatal alloimmune thrombocytopaenia (FNAIT).

Hematology-Oncology news Oncology

ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry

By MedXY 09/16/2026

In AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acute GvHD incidence.

Hematology-Oncology news

Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG Strategies

By MedXY 09/16/2026

A large registry analysis supports post-transplant cyclophosphamide (PTCy) as an effective alternative to anti-thymocyte globulin (ATG) for preventing graft-versus-host disease (GVHD) in reduced-intensity conditioning matched donor peripheral blood stem cell transplantation for AML and MDS.

Clinical Updates Hematology-Oncology news

Germline Lymphoma-Predisposing Variants: Influence on Age at Diagnosis and Survival Outcomes in Pediatric Patients

By MedXY 09/16/2026

This review synthesizes current evidence on germline lymphoma-predisposing variants, highlighting their impact on earlier cancer onset and variable survival rates in pediatric lymphoma patients, underscoring implications for genetic screening and personalized management.

Hematology-Oncology news Oncology

Comparing CHOP and CHOEP/EPOCH Regimens in Aggressive Adult T-Cell Leukemia/Lymphoma: Insights from an International Cohort Study

By MedXY 09/16/2026

This international cohort study evaluates the effectiveness of CHOEP/EPOCH versus CHOP chemotherapy in aggressive adult T-cell leukemia/lymphoma, revealing subtype-specific survival benefits in lymphomatous ATL but inconclusive results in acute ATL.

Hematology-Oncology news Pediatrics

Unraveling the Role of Cohesin Mutations in HLA-Class II Downregulation and Leukemia Progression in Down Syndrome

By MedXY 09/16/2026

This article explores how cohesin mutations impair HLA-class II gene expression, contributing to leukemic progression from transient abnormal myelopoiesis to myeloid leukemia in children with Down syndrome.

Hematology-Oncology news Pediatrics

Tisagenlecleucel for Post-Transplant Relapse in Young Acute Lymphoblastic Leukemia Patients: European Real-World Determinants of Outcome

By MedXY 09/16/2026

This study evaluates the outcomes and critical factors influencing the success of tisagenlecleucel therapy for children and young adults with B-cell acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplant across Europe.

Hematology-Oncology news

FAP-1 Deficiency: A Novel Mechanistic Link to Impaired Megakaryocyte Maturation, Platelet Dysfunction, and Myelofibrosis-like Disease

By MedXY 09/16/2026

Loss of FAP-1 disrupts megakaryocyte membrane development and platelet function through aberrant Src activation, leading to myelofibrosis-like pathology with potential therapeutic targeting by Src inhibition.

Cardiology Hematology-Oncology news

Targeting ACKR3/CXCR7 Enhances Platelet Anticoagulant Lipids and Modulates Procoagulant Function: Implications for Thrombosis Management

By MedXY 09/16/2026

Pharmacological activation of CXCR7 regulates platelet lipid metabolism, preserves mitochondrial function, and reduces procoagulant activity, offering a novel therapeutic strategy to mitigate thrombotic risk in cardiovascular diseases.

Cardiology Hematology-Oncology news

Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis: A Precision Medicine Imperative

By MedXY 09/14/2026

Clonal hematopoiesis of indeterminate potential (CHIP) poses a novel cardiovascular risk. This article explores challenges and strategies for designing cardiovascular outcomes trials tailored to CHIP’s genetic heterogeneity and clinical complexity.

Hematology-Oncology news Oncology

International Consensus on Management of Soft Tissue and Visceral Leiomyosarcomas: Key Recommendations from the Leiomyosarcoma Global Consensus Group (2026)

By MedXY 09/14/2026

An international, evidence-driven consensus harmonizes diagnostic and treatment approaches for soft tissue and visceral leiomyosarcoma, emphasizing multidisciplinary care, site-specific strategies, and priorities for research.

Hematology-Oncology Internal Medicine news

Hemoglobin Levels and Mortality Risk: Insights from a Large UK Cohort Study

By MedXY 09/13/2026

A UK prospective cohort study reveals a U-shaped association between hemoglobin concentration and mortality, with both low and high levels linked to increased death risk across age and sex groups.

$Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis$

Hematology-Oncology news

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis

By MedXY 09/13/2026

Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and safety profiles tied to disease burden and biological risk.

Hematology-Oncology news

Evolving Epidemiology and Survival Trends in Myeloproliferative Neoplasms: Insights from SEER 2000-2021

By MedXY 09/13/2026

Analysis of SEER data from 2000-2021 reveals incidence, survival trends, and demographic disparities in US patients with myeloproliferative neoplasms, highlighting improved outcomes particularly in primary myelofibrosis and areas for further research.

Hematology-Oncology news

Targeting PRMT9 to Overcome Venetoclax Resistance in AML: A Paradigm Shift in Therapeutic Strategy

By MedXY 09/13/2026

PRMT9-mediated arginine methylation drives venetoclax resistance in AML by altering RNA splicing and protein synthesis. Targeting PRMT9 restores venetoclax sensitivity, offering a promising approach to combat resistant AML.

Hematology-Oncology news

Lymph Node Assessment and Survival Outcomes in Favorable Histology Wilms Tumor: Insights from a Large COG Renal Tumor Study

By MedXY 09/13/2026

This study evaluates how the number and positivity of lymph nodes affect survival outcomes in over 2,000 patients with stage I–III favorable histology Wilms tumor, underscoring the need for standardized lymph node sampling in surgical staging.